{"id":"W4387882142","doi":"10.1016/j.annonc.2023.10.117","title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; American College of Radiology Imaging Network; Society for Immunotherapy of Cancer; Pfizer Japan; Genentech; Mirati Therapeutics; Jounce Therapeutics; Chugai Pharmaceutical; MSD K.K.; Jazz Pharmaceuticals; Eli Lilly Japan; ECOG-ACRIN Cancer Research Group; Janssen Biotech; Helsinn; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Janssen Research and Development; EMD Serono; International Association for the Study of Lung Cancer; Sanofi; Amgen; Pfizer","keywords":"Medicine; Carboplatin; Chemotherapy; Internal medicine; Pemetrexed; Oncology; Chemotherapy regimen; Lung cancer; Hazard ratio; Osimertinib; Regimen; Progression-free survival; Phases of clinical research; Cancer; Cisplatin; Erlotinib; Epidermal growth factor receptor; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002013437,0.001270901,0.00182608,0.0003988167,0.0002654324,0.0009389222,0.0006677229,0.0007543507,0.001754431],"category_scores_gemma":[0.0008833421,0.0004083832,0.00188704,0.0003844203,0.0007129812,0.000785239,0.0003086557,0.002345682,0.0003931198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008775276,"about_ca_system_score_gemma":0.001139904,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007171694,"about_ca_topic_score_gemma":0.002464771,"domain_scores_codex":[0.9995885,0.0002130845,0.00002708515,0.00006265951,0.00004279055,0.00006590124],"domain_scores_gemma":[0.999329,0.0001434516,0.0001452014,0.00005353084,0.00003181039,0.0002969929],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8588868,0.03062177,0.01074895,0.0007793661,0.003249476,0.0001469107,0.0001907771,0.001745843,0.01676963,0.0001368879,0.001796055,0.07492759],"study_design_scores_gemma":[0.5528408,0.4065684,0.03045716,0.00007928099,0.002598305,0.0002746813,0.00006930803,0.001347148,0.003433614,0.0001866316,0.002107574,0.00003707797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955914,0.00275618,0.0001499903,0.0001581119,0.00006014439,0.0003596093,0.0002779492,0.00002319697,0.0006233572],"genre_scores_gemma":[0.994212,0.002439301,0.0004263915,0.0003409479,0.0001509175,0.0004912633,0.001035654,0.00001602902,0.0008876228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002013437,"threshold_uncertainty_score":0.01064819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03675421611862686,"score_gpt":0.4300967680827514,"score_spread":0.3933425519641245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}